Bayesian Capital Management’s Novavax NVAX Stock Holding History

Bayesian Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,374	Closed	-$117K	–	200
2025 Q4	$117K	Buy	17,374 +7,100	+69%	+$53.5K	0.27%	102
2025 Q3	$89.1K	Buy	+10,274	New	+$80K	0.02%	491
2025 Q2	–	Sell	-51,500	Closed	-$330K	–	772
2025 Q1	$330K	Buy	+51,500	New	+$426K	0.05%	370
2024 Q3	–	Sell	-25,200	Closed	-$319K	–	940
2024 Q2	$319K	Buy	+25,200	New	+$254K	0.04%	490
2023 Q4	–	Sell	-83,300	Closed	-$603K	–	948
2023 Q3	$603K	Buy	83,300 +55,200	+196%	+$441K	0.07%	335
2023 Q2	$209K	Buy	+28,100	New	+$221K	0.02%	632
2022 Q3	–	Sell	-15,374	Closed	-$791K	–	926
2022 Q2	$791K	Sell	15,374 -14,009	-48%	-$726K	0.15%	209
2022 Q1	$2.16M	Buy	+29,383	New	+$2.62M	0.32%	58
2021 Q4	–	Sell	-4,846	Closed	-$1M	–	477
2021 Q3	$1M	Buy	+4,846	New	+$1.07M	0.29%	89
2020 Q4	–	Sell	-13,400	Closed	-$1.45M	–	613
2020 Q3	$1.45M	Buy	+13,400	New	+$1.63M	0.35%	69
2019 Q1	–	Sell	-1,130	Closed	-$42K	–	694
2018 Q4	$42K	Buy	+1,130	New	+$43.8K	0.01%	582
2017 Q3	–	Sell	-1,145	Closed	-$26K	–	597
2017 Q2	$26K	Buy	+1,145	New	+$22.5K	0.01%	399

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's NVAX Position: Q1 2026 in Review

Bayesian Capital Management sold out of Novavax (NVAX) in Q1 2026, closing a stake of 17,374 shares — an estimated $117K sold.

Bayesian Capital Management first reported a position in NVAX in Q2 2017 and held it in 12 quarters. The position peaked at $2.16M in Q1 2022. 259 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Bayesian Capital Management reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
Bayesian Capital Management sold 17,374 Novavax shares in Q1 2026, an estimated $117K.
Bayesian Capital Management first reported a position in Novavax in Q2 2017 and held it in 12 quarters.
Bayesian Capital Management's Novavax position peaked at $2.16M in Q1 2022.
259 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.